Check out your Company Bowl for anonymous work chats.
Tris Pharma announced the FDA has approved Onyda XR, a once-daily extended-release oral suspension of clonidine hydrochloride for the treatment of attention-deficit/hyperactivity disorder (ADHD) as a monotherapy, or as an adjunctive therapy to approved central nervous system (CNS) stimulant medications in pediatric patients over the age of six years. The regulatory action marks the first time that a liquid non-stimulant ADHD medication has become available in the United States. According to Tris Pharma, its LiquiXR technology provides flexibility with nighttime dosing that caters to individual patient needs and provides a smooth, extended-release profile.
FDA Approves Tris Pharma's Onyda XR, a Once-Daily, Extended-Release Oral Suspension for the Treatment of ADHD
Tris Pharma Inc has announced a licensing agreement with Braingaze Ltd and the establishment of Tris Digital Health. Tris Digital Health will concentrate on developing and distributing digital diagnostic and therapeutic products for the treatment of attention-deficit/hyperactivity disorder (ADHD) and other neurological health disorders.
Tris Digital Health Forms, Will Focus on Digital Diagnostic Platform for ADHD
Tris Pharma Launches Digital Health Business: Through licensing agreement with Braingaze aims to develop and commercialize digital products for ADHD.
Tris Pharma Launches Digital Health Business
Cranbury, a new subsidiary of Tris Pharma, will market more than 20 generic medicines and advance a diverse pipeline transitioned from Tris. Deflazacort oral suspension is indicated to treat patients five years of age and older for Duchenne muscular dystrophy, a rare disease with limited treatment options available. Immediate commercial availability of therapy underscores Cranbury’s commitment to providing patients with access to effective generic medicines across multiple disease states.
Cranbury Pharmaceuticals Receives U.S. FDA Approval for First Generic Version of Emflaza® Oral Suspension (deflazacort) for Duchenne Muscular Dystrophy | BioBuzz
Tris Pharma appoints Michael Magee as vice president, quality & compliance
Tris Pharma appoints Michael Magee as vice president, quality & compliance | ROI-NJ
Tris Pharma starts two Phase III registrational trials for pain therapy: The two-Phase III studies will evaluate the company’s dual-NMR agonist, cebranopadol, as treatment for moderate-to-severe acute pain.
Tris Pharma starts two Phase III registrational trials for pain therapy
“I want to extend my heartfelt thank you to all Tris employees for adapting as quickly as you have to the changing environment, both at work and at home. I’m certain for many of you this has come with its own set of unique challenges and I’d like to remind you that you have Tris’ support in assisting you through this. What we are living on a daily basis is truly a “we’re all in this together” situation and together we will manage and persevere. Please remember that first and foremost the most important consideration for all our actions continues to be each of you.” - Ketan Mehta Tris Founder and CEO
Quillivant XR®, QuilliChew ER® and Dyanavel® XR are 100% Made in the U.S.A. and Remain Consistently Supplied During COVID-19 Pandemic
News
For all available opportunities within Tris Pharma, please visit our website.
Tris Pharma